Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexavar with TACE in unresectable HCC
NCT01004978Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2009
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Oct 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01004978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004978.